A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
收藏DataCite Commons2025-04-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009781/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The objective of this study was to evaluate the safety and efficacy of multiple doses of
upadacitinib monotherapy versus placebo in the treatment of adults with moderate to severe
atopic dermatitis (AD).
提供机构：
Vivli
创建时间：
2024-01-23
